Donate

Two New Sites Available for Early Access to Alpharadin

There are now two new, additional sites added to the Early Access Trial of the investigational treatment known as Radium-233 or Alpharadin for men with castrate resistant prostate cancer with multiple bone metastases. This post contains the most up to date and accurate information, the clinical trials.gov site is NOT currently accurate. Additionally, there are [...]

Two New Sites Open for Early/Expanded Access to Radium-233 (Alapharedin) in Fort Meyers, FL. & Philadelphia, PA

The Early/Expanded Access Committee has been continuing to work on getting additional sites open for men with advanced prostate cancer to get access to the yet unapproved drug Radium-233 Chloride (Alapharadin). Due to the hard work of this committee there are now sites in seven different states. In order to qualify for this treatment you [...]

Now an Early Access Site for Alpharedin Opens in New York

The Early Access Committee on which Malecare sits has been successful in adding an additional site in Long Island, New York to the Early Access Trial of Radium-233 Chloride (Alpharedin) for men with advanced prostate cancer who are castrate resistant and have at least two (2) bone metastases. If you are interested in this trial [...]

Another Site Added to the Early Access Program for Radium-223 Chloride (Alpharadin)

The Early Access Committee Announces an Additional Site for Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases We have been able to get Bayer to open another early access site for Alpharedin. This additional site is in Boston, Ma. In addition to this new site there are still three other sites. [...]

New Site from the Early/Expanded Access Committee – Alpharedin Now available at Stanford University (plus 3 other sites)

There was just a new site opened for the early/expanded access program for Alpharedin (Radium-235). The new site is at Stanford University, California. This makes a total of four sites, but most of them have not been adequately supported by the drug company, Bayer. Hopefully, this site will be better supported, but if it too [...]

Four New Sites Added to the MDV3100 (Enzalutamide) Early Access Trial

The Early/Expanded Access Committee has informed me that four additional sites have been added to the trial so there are now 23 States that have an expanded access trial of MDV3100 available to men with advanced prostate cancer. The trial is designed to monitor the safety of the drug in men with progressive castration-resistant advanced [...]

Two Early Access Trials – 2 New sites for MDV-3100 & A New Early Access Trial for Radium-223 Chloride (Alpharedin)

There has been a lot of news in the area of early access for great drugs to treat advanced prostate cancer prior to the FDA’s approval. I have informed you about the Early Access Program for MDV-3100 in men with castrate resistant prostate cancer previously treated with a Docetaxel based chemotherapy agent. The latest news [...]

New Sites Added for the Early/Expanded Access Program for Enzalutamide (MDV3100)

It has just been announced that there are now two new additional sites added to the Early/Expanded Access Program for Enzalutamide (MDV3100). The program is technically a clinical trial designed to monitor MDV-3100’s safety in men with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. This means that there are now a total of [...]

Failing Zytiga – Some Requirements to Access the MDV-3100 Early Access Trial

Many of us in the United States with advanced prostate cancer who have failed Zytiga are looking to enter the Early Access MDV-3100 Clinical Trial. However, you need to be aware that there are some requirements you will need to meet prior to starting MDV-3100. You will need to wait 30 days after stopping Zytiga [...]

New Site Added for the Early/Expanded Access Trial of Enzalutamide (MDV-3100)

The Early/Expanded Access Committee has announced the addition of a new site in Atlanta, Ga for the trial of MDV-3100. According to my sources, there will be even more sites added in the near future. The role of the trial is to provide expanded Access to MDV3100 and monitor its safety in men with progressive [...]

Go to Top